GlassScriptPhysician profile
Oscar Leis
NPI 1598148892
$3,608.86
in general payments reported to CMS, 2019-2025
20 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $162 · 2021: $298 · 2022: $870 · 2023: $471 · 2024: $334 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $605.94 | 2019-2025 | Cequa, Xelpros |
| Abbvie INC. | $484.77 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $368.82 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $322.09 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $273.30 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $248.08 | 2019-2025 | Tryptyr, Precision 1, Eysuvis |
| Harrow Eye, LLC | $237.50 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $220.10 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $144.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $107.90 | 2019-2022 | |
| Allergan, INC. | $83.02 | 2021 | |
| Coopervision INC. | $82.43 | 2025 | Onefit Contact Lens, Synergeyes Contact Lens |
| Dompe US, INC. | $78.13 | 2025 | Oxervate |
| Sight Sciences, INC. | $70.83 | 2022-2023 | Tearcare System |
| Eyevance Pharmaceuticals LLC | $68.33 | 2019-2023 | Tobradex St |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $62.02 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $53.48 | 2022-2025 | |
| Biotissue Holdings INC. | $38.30 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $37.94 | 2022 | |
| Kala Pharmaceuticals, INC. | $21.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Leis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.